Andrew M. Green, serving as the Senior Vice President of Regulatory and Quality at Artivion, Inc. (NASDAQ:AORT), executed a significant transaction involving the company's common stock on June 11, 2026. Mr. Green disposed of a total of 44,001 shares, resulting in proceeds amounting to $910,738. These sales were facilitated through a pre-arranged Rule 10b5-1 trading plan, a mechanism designed to allow insiders to trade company stock during periods when they might otherwise be restricted.
The execution of these sales occurred at weighted average prices ranging between $20.694 and $20.707 per share. The actual transaction prices for the individual shares varied, falling within a range of $20.24 to $21.02. This activity takes place against the backdrop of Artivion's stock trading near $20.62, a level that represents a substantial decline of 56% over the past six months from its 52-week high of $48.25. According to InvestingPro analysis, which provides comprehensive insights on over 1,400 US stocks including detailed Pro Research Reports, analysts maintain price targets between $36 and $48. This range suggests significant upside potential from current levels, despite the recent downward trajectory of the stock.
Prior to these sales, Mr. Green acquired the 44,001 shares of common stock through the exercise of stock options. The total value of these option exercises amounted to $589,078. The exercise prices for these options varied, ranging from $11.03 to $18.44 per share. Specifically, 14,001 shares were acquired from options with an exercise price of $18.44, which first became exercisable on February 23, 2023. Another 30,000 shares were acquired from options with an exercise price of $11.03, which first became exercisable on November 8, 2023. All option exercises and subsequent sales reported were effected pursuant to the same Rule 10b5-1 trading plan adopted by Mr. Green on March 12, 2026.
In other recent developments, Artivion Inc. reported its first-quarter revenue of $116.3 million. This figure slightly missed Canaccord's estimate of $117.1 million but aligned with the consensus expectation of $115.7 million. The company also reported an adjusted EBITDA of $22.1 million, which surpassed Canaccord's estimate of $19.1 million, though it fell short of the consensus estimate of $23.0 million. Following these results, Canaccord lowered its price target for Artivion from $48 to $36 while maintaining a Buy rating.
Additionally, Artivion completed the acquisition of Endospan, a company focused on endovascular solutions for aortic pathologies, for $135 million upfront. This acquisition includes potential additional payments contingent on the commercial performance of Endospan's NEXUS Aortic Arch System. In a separate development, Stifel reiterated a Buy rating on Artivion with a $45 price target after surveying surgeons about the company's AMDS device. The survey was conducted after Artivion reduced its full-year guidance due to lower-than-expected adoption of the AMDS device. Furthermore, during its 2026 Annual Meeting of Stockholders, Artivion announced the election of all nominated directors and approved executive compensation.